Portfolio Company of Biofund RVC National BioService (NBS) will provide an opportunity for accelerated testing of anti-coronavirus medicines and test systems that Russian developers are working on today. Reducing the duration of preclinical studies and technical testing will be possible through the use of tissue microchips.
National BioService has become the first company to organize the production of tissue microchips in Russia. Microchips are a set of different tissues that are packaged on a unique substrate. Previously, to see how medicine interacts with 60 tissue samples, at least 60 experiments had to be done. Now, this set of tissues can be placed on one microchip and get accurate results in one experiment. On average, it takes several years to develop new vaccines, and medicine development can take up to 10 years. Tissue microchips make it possible to go through some stages of drug testing much faster.
NBS already fulfills orders of many leading domestic and foreign biopharmaceutical companies, research institutes for the design, production, and use of tissue microchips on its laboratory base. In 2017-18, by the order of N.F.Gamaleya Federal Research Center for Epidemiology and Microbiology, NBS, took an active part in the development of the Russian medicine against Ebola fever. The company conducted a preclinical study of the cross-reactivity of this medicine.
The National BioService is the first Russian wide-profile commercial research biobank. The company is included in the portfolio of Biofund RVC since 2013. It has been a resident of the Skolkovo Technopark since 2015. In 2018, NBS received support under the Road Map Healthnet National Technology Initiative (NTI).